Labiotech.eu

GARDP Antibiotic Resistance Europe Germany

News and Trends 6 Sep 2017

Europe Gives the Antibiotic Resistance Fight a Major Cash Injection

Six European countries, the UK’s Wellcome Trust and South Africa have committed €56.5M to the GARDP to work on breaking antibiotic resistance. The Global Antibiotic Research and Development Partnership (GARDP) has received this week €56.5M of funding to boost its activity, focused in promoting the development of new antibiotics. The investment comes mainly from Germany, […]

September 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Sep 2017

What to Do When the Microorganisms Get to You

For the first time ever an injectable clinical batch has been manufactured with the help of single-use technologies. A great way of fighting unwanted contamination in drug development! Have you ever opened a petri-dish and found an unknown growth on your medium? The same medium you had carefully prepared by meticulously spreading the sample over […]

September 6, 2017 - 5 minutesmins - By External Contributor

Interview 6 Sep 2017

The CAR-T Race is Far from Over: This CEO is Exploring a New Avenue

Gilead has just splashed out $12 billion for Kite Pharma, and the FDA is currently reviewing Novartis’ Marketing Approval Application for the first-ever CAR-T therapy. I sat down with Gregg Sando of Cell Medica to hear the perspective of a biotech vying for a piece of the pie. Though he spent 20 years in investment […]

September 6, 2017 - 6 minutesmins - By Evelyn Warner

News and Trends 5 Sep 2017

FREE TICKET Giveaway – European Antibody Congress

Our wonderful readers now have the chance to win a FREE ticket for the European Antibody Congress in Basel, Switzerland! On 31st October – 2nd November you will have the opportunity to participate in a vibrant gathering with more than 200 speakers and 650 influential decision makers from across academia and the biotech and pharmaceutical industry! Apply today and […]

September 5, 2017 - 2 minutesmins - By External Contributor

Inventiva fibrosis abbvie boehringer ingelheim

News and Trends 5 Sep 2017

French Biotech Lures Big Pharma with Fibrosis Treatments

This week, Inventiva has received a milestone payment from Boehringer Ingelheim and extended its collaboration with AbbVie. Today, Boehringer Ingelheim has decided today to take the next step forward and start development of the first candidate against idiopathic pulmonary fibrosis (IPF) from a research partnership with Inventiva. This has triggered a €2.5M payment for the French biotech, which is […]

September 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández

AMAL Therapeutics Cancer Vaccine Series B

News and Trends 5 Sep 2017

Swiss Biotech Raises €8M in First Closing of Series B to Develop Cancer Vaccines

AMAL Therapeutics has raised €8M to push its colorectal cancer vaccine ATP128 into clinical trials and keep developing its tumor vaccine pipeline. AMAL Therapeutics, a young biotech based in Geneva, is getting a boost for its pipeline of cancer vaccines thanks to a new funding round. The first tranche of its Series B fundraising has gathered €8M (CHF 8.8M) […]

September 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 5 Sep 2017

UPDATE: Austrian Biotech receives €3.3M boost for its Chikungunya Vaccine

UPDATE (05/09/2017): Innovate UK has granted Themis £3M (€3.3M) to push its Chikungunya Vaccine towards Phase III. Originally Published 06/06/2017 Themis Bioscience will test its vaccine candidate against Chikungunya fever in a new Phase I/II trial sponsored by the NIH. Based in Vienna, Themis Bioscience develops new vaccine candidates for emerging diseases like Zika and Chikungunya with its virus […]

September 5, 2017 - 3 minutesmins - By Melanie De Almeida

epigenetics review cambridge epigenetix oryzon1

In Depth 5 Sep 2017

The Next Generation of Genetic Medicine: A Review of Epigenetics

The field of genetics has long been an object of global fascination, beginning with Mendel’s pea plant experiments in the 19th century and peaking when the human genome was sequenced (albeit not completely) in 2003. But epigenetics as the next level up from genetics is still mysterious to most. Efforts are already underway to make […]

September 5, 2017 - 9 minutesmins - By Evelyn Warner

destiny pharma new antibiotics mrsa london stock1

News and Trends 4 Sep 2017

British Biotech Developing New Antibiotics Enters the London Stock Exchange

Destiny Pharma has started trading on the London Stock Exchange to support its search for new antibiotics that can fight resistant bacteria like MRSA. Destiny Pharma, based in Brighton, UK, has entered the AIM market of the London Stock Exchange with an initial placement of £15.3M (€16.7M), which put its starting market cap at £65.4M […]

September 4, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Sep 2017

Record Momentum for European Biotech

The European biotech sector has had a bumpy past. Today, however it has reached a record momentum and is flourishing like never before. Stock exchanges, such as Euronext, support Biotech companies and have contributed largely to the record high we see today. The global financial crisis hit Europe in 2008. Like a tidal wave, it […]

September 4, 2017 - 10 minutesmins - By External Contributor

Interview 4 Sep 2017

Meet this Blockbuster Developer turned Partner at a Headlining VC

Kevin Johnson told me the story and lessons of his career, from CTO of Cambridge Antibody Technology to General Partner at Medicxi. Since starting his biotech career as the lead developer of one of biotech’s biggest success stories, Humira, Kevin Johnson has continued in biotech as a force to be reckoned with. He joined the […]

September 4, 2017 - 7 minutesmins - By Evelyn Warner

Allergan Heptares Therapeutics alzheimers

News and Trends 1 Sep 2017

Allergan Takes to the Clinic a New Alzheimer’s Drug from a €3Bn Deal

Allergan’s partner Heptares Therapeutics has dosed the first patient with a GPCR drug to treat major symptoms of Alzheimer’s disease. A year ago, Allergan signed a massive deal of up to €3Bn with Heptares Therapeutics for the development of drugs that target G-protein-coupled receptors (GPCRs), a protein superfamily that currently comprises the target of around […]

September 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Europe Gives the Antibiotic Resistance Fight a Major Cash Injection

What to Do When the Microorganisms Get to You

The CAR-T Race is Far from Over: This CEO is Exploring a New Avenue

FREE TICKET Giveaway – European Antibody Congress

French Biotech Lures Big Pharma with Fibrosis Treatments

Swiss Biotech Raises €8M in First Closing of Series B to Develop Cancer Vaccines

UPDATE: Austrian Biotech receives €3.3M boost for its Chikungunya Vaccine

The Next Generation of Genetic Medicine: A Review of Epigenetics

British Biotech Developing New Antibiotics Enters the London Stock Exchange

Record Momentum for European Biotech

Meet this Blockbuster Developer turned Partner at a Headlining VC

Allergan Takes to the Clinic a New Alzheimer’s Drug from a €3Bn Deal

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!